Zentalis Pharmaceuticals, Inc. Deferred Federal Income Tax Expense (Benefit)
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was $0.00.
- Zentalis Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $0.00.
- Zentalis Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was -$891.00K.
- Zentalis Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was -$683.00K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-26 |
| 2023-12-31 | -$891.00K 10-K · filed 2026-03-26 |
| 2022-12-31 | -$683.00K 10-K · filed 2025-03-26 |
| 2021-12-31 | -$120.00K 10-K · filed 2024-02-27 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |